Top

Clinical and Translational Oncology

Published in:

01-07-2018 | Research Article

Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients

Authors: M. Wang, S. Ji, G. Shao, J. Zhang, K. Zhao, Z. Wang, A. Wu

Published in: Clinical and Translational Oncology | Issue 7/2018

Abstract

Purpose

Exosomes are gradually detected as an indicator for diagnosis and prognosis of breast cancer in clinic and a systematic review was conducted.

Methods

A search for clinical studies published before July 1, 2017 was performed. Methods of exosome purification and identification from all studies were extracted. For diagnosis evaluation, the comparison of exosome biomarkers expression between breast cancer patients and healthy women was obtained; for prognosis prediction, the correlation between exosome biomarkers expression and chemotherapy resistance, overall survival (OS), disease-free survival (DFS), recurrence and metastasis of breast cancer was also extracted.

Results

A total of 11 studies with 921 breast cancer patients were included. Ultracentrifugation is the most frequent method to purify exosomes and transmission electron microscopy is commonly used to identify exosomes. Exosome biomarkers (such as HER2, CD47, Del-1, miR-1246 and miR-21) in breast cancer patients are significantly higher than those in healthy controls, exosomal GSTP1 and TRPC5 are related to chemotherapy resistance, exosome-carrying TRPC5, NANOG, NEUROD1, HTR7, KISS1R and HOXC are correlated to PFS, DFS or OS, and some exosomal proteins (HER2, KDR, CD49d, CXCR4 and CD44) as well as miRNAs (miR-340-5p, miR-17-5p, miR-130a-3p, miR-93-5p) are associated with tumor recurrence or distant organ metastasis.

Conclusions

Exosome biomarkers can be used for early diagnosis and prognosis of breast cancer patients in clinic.

Harbeck N, Gnant M. Breast cancer. Lancet. 2017;18(389):1134–50. https://doi.org/10.1016/S0140-6736(16)31891-8.CrossRef

Rugo HS, Olopade OI, DeMichele A, Yau C, van ‘t Veer LJ, Buxton MB, et al. Adaptive randomization of veliparib–carboplatin treatment in breast cancer. N Engl J Med. 2016;375(1):23–34. https://doi.org/10.1056/NEJMoa1513749.CrossRefPubMedPubMedCentral

Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, et al. Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res. 2016;18(1):90. https://doi.org/10.1186/s13058-016-0753-x.CrossRefPubMedPubMedCentral

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48. https://doi.org/10.1056/NEJMra1001389.CrossRefPubMed

Hannafon BN, Ding WQ. Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci. 2013;14(7):14240–69. https://doi.org/10.3390/ijms140714240.CrossRefPubMedPubMedCentral

Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329–35. https://doi.org/10.1038/nature15756.CrossRefPubMedPubMedCentral

Donnarumma E, Fiore D, Nappa M, Roscigno G, Adamo A, Iaboni M, et al. Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Oncotarget. 2017;8(12):19592–608. https://doi.org/10.18632/oncotarget.14752.CrossRefPubMedPubMedCentral

Goodarzi H, Nguyen HC, Zhang S, Dill BD, Molina H, Tavazoie SF. Modulated expression of specific tRNAs drives gene expression and cancer progression. Cell. 2016;165(6):1416–27. https://doi.org/10.1016/j.cell.2016.05.046.CrossRefPubMedPubMedCentral

Bliss SA, Sinha G, Sandiford OA, Williams LM, Engelberth DJ, Guiro K, et al. Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Can Res. 2016;76(19):5832–44. https://doi.org/10.1158/0008-5472.can-16-1092.CrossRef

10.

Huang MB, Gonzalez RR, Lillard J, Bond VC. Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells. Oncotarget. 2017;8(7):11302–15. https://doi.org/10.18632/oncotarget.14513.PubMedPubMedCentralCrossRef

11.

Lowry MC, Gallagher WM, O’Driscoll L. The role of exosomes in breast cancer. Clin Chem. 2015;61(12):1457–65. https://doi.org/10.1373/clinchem.2015.240028.CrossRefPubMed

12.

Liberati AAD, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34. https://doi.org/10.1016/j.jclinepi.2009.06.006.CrossRefPubMed

13.

Fang S, Tian H, Li X, Jin D, Li X, Kong J, et al. Clinical application of a microfluidic chip for immunocapture and quantification of circulating exosomes to assist breast cancer diagnosis and molecular classification. PLoS ONE. 2017;12(4):e0175050. https://doi.org/10.1371/journal.pone.0175050.CrossRefPubMedPubMedCentral

14.

Domenyuk V, Zhong Z, Stark A, Xiao N, O’Neill HA, Wei X, et al. Plasma exosome profiling of cancer patients by a next generation systems biology approach. Sci Rep. 2017;7:42741. https://doi.org/10.1038/srep42741.CrossRefPubMedPubMedCentral

15.

Lee SJ, Lee J, Jung JH, Park HY, Lee C-H, Moon P-G, et al. Exosomal Del-1 as a potent diagnostic marker for breast cancer: a prospective cohort study. J Clin Oncol. 2017;35(15_suppl):11548. https://doi.org/10.1200/JCO.2017.35.15_suppl.11548.

16.

Kibria G, Ramos EK, Lee KE, Bedoyan S, Huang S, Samaeekia R, et al. A rapid, automated surface protein profiling of single circulating exosomes in human blood. Sci Rep. 2016;6:36502. https://doi.org/10.1038/srep36502.CrossRefPubMedPubMedCentral

17.

Yang SJ, Wang DD, Li J, Xu HZ, Shen HY, Chen X et al. Predictive role of GSTP1-containing exosomes in chemotherapy-resistant breast cancer. Gene. 2017. https://doi.org/10.1016/j.gene.2017.04.031.

18.

Wang T, Ning K, Lu TX, Sun X, Jin L, Qi X, et al. Increasing circulating exosomes-carrying TRPC5 predicts chemoresistance in metastatic breast cancer patients. Cancer Sci. 2017;108(3):448–54. https://doi.org/10.1111/cas.13150.CrossRefPubMedPubMedCentral

19.

Ning K, Wang T, Sun X, Zhang P, Chen Y, Jin J et al. UCH-L1-containing exosomes mediate chemotherapeutic resistance transfer in breast cancer. J Surg Oncol. 2017. https://doi.org/10.1002/jso.24614.

20.

Sueta A, Yamamoto Y, Tomiguchi M, Takeshita T, Ibusuki M, Iwase H. Differential expression of exosomal miRNAs between breast cancer patients with recurrence and no-recurrence. Cancer Res. 2017;77:4. https://doi.org/10.1158/1538-7445.SABCS16-P1-02-13.

21.

Gerratana L, Toffoletto B, Bulfoni M, Cesselli D, Beltrami AP, Di Loreto C, et al. Metastatic breast cancer and circulating exosomes. Hints from an exploratory analysis. Ann Oncol. 2015;26:23–5. https://doi.org/10.1093/annonc/mdv336.37.CrossRef

22.

Rodriguez M, Silva J, Herrera A, Herrera M, Pena C, Martin P, et al. Exosomes enriched in stemness/metastatic-related mRNAS promote oncogenic potential in breast cancer. Oncotarget. 2015;6(38):40575–87. https://doi.org/10.18632/oncotarget.5818.CrossRefPubMedPubMedCentral

23.

Kanbayashi C, Iwata H. Current approach and future perspective for ductal carcinoma in situ of the breast. Jpn J Clin Oncol. 2017. https://doi.org/10.1093/jjco/hyx059.

24.

Kazarian A, Blyuss O, Metodieva G, Gentry-Maharaj A, Ryan A, Kiseleva EM, et al. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. Br J Cancer. 2017;116(4):501–8. https://doi.org/10.1038/bjc.2016.433.CrossRefPubMedPubMedCentral

25.

Orlando L, Viale G, Bria E, Lutrino ES, Sperduti I, Carbognin L, et al. Discordance in pathology report after central pathology review: implications for breast cancer adjuvant treatment. Breast. 2016;30:151–5. https://doi.org/10.1016/j.breast.2016.09.015.CrossRefPubMed

26.

Navani N, Nankivell M, Woolhouse I, Harrison RN, Munavvar M, Oltmanns U, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for the diagnosis of intrathoracic lymphadenopathy in patients with extrathoracic malignancy: a multicenter study. J Thorac Oncol. 2011;6(9):1505–9. https://doi.org/10.1097/JTO.0b013e318223c3fe.CrossRefPubMedPubMedCentral

27.

Martin M, Ito H. Incidentally discovered intraperitoneal masses. JAMA Surg. 2015;150(7):677–8. https://doi.org/10.1001/jamasurg.2015.0260.CrossRefPubMed

28.

Tang S, Wei L, Sun Y, Zhou F, Zhu S, Yang R, et al. CA153 in breast secretions as a potential molecular marker for diagnosing breast cancer: a meta analysis. PLoS ONE. 2016;11(9):e0163030. https://doi.org/10.1371/journal.pone.0163030.CrossRefPubMedPubMedCentral

29.

Fang C, Cao Y, Liu X, Zeng XT, Li Y. Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes. Oncotarget. 2017. https://doi.org/10.18632/oncotarget.19246.

30.

Zhang L, Pan L, Xiang B, Zhu H, Wu Y, Chen M, et al. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. Oncotarget. 2016;7(21):30876–91. https://doi.org/10.18632/oncotarget.9021.PubMedPubMedCentralCrossRef

31.

Wen SW, Sceneay J, Lima LG, Wong CS, Becker M, Krumeich S, et al. The biodistribution and immune suppressive effects of breast cancer-derived exosomes. Can Res. 2016;76(23):6816–27. https://doi.org/10.1158/0008-5472.can-16-0868.CrossRef

32.

Ohuchi N, Suzuki A, Sobue T, Kawai M, Yamamoto S, Zheng YF, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. Lancet. 2016;387(10016):341–8. https://doi.org/10.1016/s0140-6736(15)00774-6.CrossRefPubMed

33.

Aktas B, Kasimir-Bauer S, Muller V, Janni W, Fehm T, Wallwiener D, et al. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. BMC Cancer. 2016;16:522. https://doi.org/10.1186/s12885-016-2587-4.CrossRefPubMedPubMedCentral

34.

Madic J, Kiialainen A, Bidard FC, Birzele F, Ramey G, Leroy Q, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer. 2015;136(9):2158–65. https://doi.org/10.1002/ijc.29265.CrossRefPubMed

35.

Chollet-Hinton L, Anders CK, Tse CK, Bell MB, Yang YC, Carey LA, et al. Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case–control study. Breast Cancer Res. 2016;18(1):79. https://doi.org/10.1186/s13058-016-0736-y.CrossRefPubMedPubMedCentral

36.

Natrajan R, Sailem H, Mardakheh FK, Arias Garcia M, Tape CJ, Dowsett M, et al. Microenvironmental heterogeneity parallels breast cancer progression: a histology-genomic integration analysis. PLoS Med. 2016;13(2):e1001961. https://doi.org/10.1371/journal.pmed.1001961.CrossRefPubMedPubMedCentral

37.

Meng F, Liu B, Xie G, Song Y, Zheng X, Qian X et al. Amplification and overexpression of PSCA at 8q24 in invasive micropapillary carcinoma of breast. Breast Cancer Res Treat. 2017. https://doi.org/10.1007/s10549-017-4407-1.

38.

Lee MV, Katabathina VS, Bowerson ML, Mityul MI, Shetty AS, Elsayes KM, et al. BRCA-associated cancers: role of imaging in screening, diagnosis, and management. Radiographics. 2017;37(4):1005–23. https://doi.org/10.1148/rg.2017160144.CrossRefPubMed

39.

Reyes ME, Fujii T, Branstetter D, Krishnamurthy S, Masuda H, Wang X, et al. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Res Treat. 2017;164(1):57–67. https://doi.org/10.1007/s10549-017-4233-5.CrossRefPubMed

Title: Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients
Authors: M. Wang
S. Ji
G. Shao
J. Zhang
K. Zhao
Z. Wang
A. Wu
Publication date: 01-07-2018
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 7/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1805-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2018

Correction to: SEOM clinical guidelines for anaplastic gliomas (2017)

Morphine: double-faced roles in the regulation of tumor development

Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients

Correction to: Curative radiation therapy for very elderly bladder cancer patients with localized disease

Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer

Curative radiation therapy for very elderly bladder cancer patients with localized disease

Keynote webinar | Spotlight on antibody–drug conjugates in cancer